Pipeline In Alzheimer’s, Bristol Myers sees big promise beyond amyloid BioPharma DiveBristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.NeuroscienceRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) BioPharma Dive Bristol Myers’ neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s triple agonist shows bariatric surgery-like weight loss resultsNext: Gilead Sciences completes Tubulis acquisition for $5bn Related Stories Pipeline Sanofi drops two more programmes in R&D clear-out pharminent July 30, 2026 Pipeline Lundbeck preps for key bexicaserin data around year-end pharminent July 20, 2026 Pipeline AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist pharminent July 10, 2026
